FXN and hypercalcemia disease: Failed to improve neurological function (SARA, 9-HPT, 8-MWT, PATA) but increased FXN levels in platelets at 5.5–7.0 pg./μg dose range.5 out of 20 participants discontinued due to mild hypercalcemia.